0
No votes yet
Article

Communication and Information Needs of Women Diagnosed With Ovarian Cancer Regarding Treatment-Focused Genetic Testing

Margaret Gleeson
Bettina Meiser
Kristine Barlow-Stewart
Alison H. Trainer
Kathy Tucker
Kaaren J. Watts
Michael Friedlander
Nadine Kasparian
ONF 2013, 40(3), 275-283 DOI: 10.1188/13.ONF.40-03AP

Purpose/Objectives: To identify women's information and communication preferences about treatment-focused genetic testing (TFGT) in the ovarian cancer context.

Research Approach: A qualitative interview study.

Setting: Two familial cancer services and a gynecologic oncology clinic at a major teaching hospital in Australia.

Participants: 22 women diagnosed with ovarian cancer who had either advanced disease and had previously undergone TFGT (n = 12) or had been diagnosed in the previous 6-20 weeks with ovarian cancer and had not undergone TFGT (n = 10).

Methodologic Approach: Participants were interviewed individually about actual and hypothetical views of TFGT. The interviews were transcribed and organized into themes using qualitative analysis software.

Findings: Most women wanted to be informed about TFGT prior to their surgery for ovarian cancer. The majority preferred to receive the information verbally; slightly more women preferred their medical oncologist to deliver the information compared to a genetic specialist or oncology nurse. Women preferred the focus of pretest information to be on them and their treatment.

Conclusions: Women diagnosed with ovarian cancer want information about genetic testing early with focus placed on the potential benefits of genetic testing on treatment.

Interpretation: The findings of this study provide much-needed guidance to oncology nurses and other oncology healthcare professionals about when, what, and how information about TFGT should be delivered to patients diagnosed with ovarian cancer. Supportive patient education materials now need to be developed to assist these women in making informed decisions about genetic testing.

Knowledge Translation: Knowing that women do want TFGT, how they want it presented and by whom, and the content and level of detail that women want means that TFGT can now be presented as an option to women newly diagnosed with ovarian cancer, which may influence firstline treatment. The findings also provide the knowledge required to prepare education tools to assist oncology nurses involved in frontline care.

References 

Alsop, K., Fereday, S., Meldrum, C., DeFazio, A., Emmanuel, C., George, J., … Mitchell, G. (2012). <i>BRCA</i> mutation frequency and patterns of treatment response in <i>BRCA</i> mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology, 30</i>, 2654-2663. doi:10.1200/JCO.2011.39.8545

Andrews, L., Mireskandari, S., Jessen, J., Thewes, B., Solomon, M., Macrae, F., & Meiser, B. (2006). Impact of familial adenomatous polyposis on young adults: Attitudes to genetic testing, and support and information needs. <i>Genetics in Medicine, 8</i>, 697-703. doi:10.1097/01.gim.0000245574.75877.b9

Ardern-Jones, A., Kenen, R., & Eeles, R. (2005). Too much too soon? Patients' and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. <i>European Journal of Cancer Care, 14</i>, 272-281.

Bolton, K., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S., Karlan, B., … Pharoah, P. D. (2012). Association between <i>BRCA1</i> and <i>BRCA2</i> mutations and survival in women with invasive epithelial ovarian cancer. <i>JAMA, 307</i>, 382-390. doi:10.1001/jama.2012.20

Bonadona, V., Saltel, P., Desseigne, F., Mignotte, H., Saurin, J. C., Wang, Q., … Lasset, C. (2002). Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: Reactions and behavior after the disclosure of a positive test result. <i>Cancer Epidemiology, Biomarkers and Prevention, 11</i>, 97-104.

Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2008). Effect of <i>BRCA1/2</i> mutations on long-term survival of patients with invasive ovarian cancer: The National Israeli Study of Ovarian Cancer. <i>Journal of Clinical Oncology, 26</i>, 20-25. doi:10.1200/jco.2007.11.6905

Chionh, F., Mitchell, G., Lindeman, G. J., Friedlander, M., & Scott, C. L. (2011). The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions. <i>Asia-Pacific Journal of Clinical Oncology, 7</i>, 197-211. doi:10.1111/j.1743-7563.2011.01430.x

Coffey, A., & Atkinson, P. (1996). <i>Making sense of qualitative data: Complementary research strategies.</i> Thousand Oaks, CA: Sage.

Daniels, M. S., Urbauer, D. L., Stanley, J. L., Johnson, K. G., & Lu, K. H. (2009). Timing of <i>BRCA1/BRCA2</i> genetic testing in women with ovarian cancer. <i>Genetics in Medicine, 11</i>, 624-628. doi:10.1097/GIM.0b013e3181ab2295

Denzin, J. M., & Lincoln, Y. S. (1994). <i>Handbook of qualitative research.</i> London, England: Sage.

Elit, L., Charles, C., Dimitry, S., Tedford-Gold, S., Gafni, A., Gold, I., & Whelan, T. (2010). It's a choice to move forward: Women's perceptions about treatment decision making in recurrent ovarian cancer. <i>Psycho-Oncology, 19</i>, 318-325. doi:10.1002/pon.1562

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., … de Bono, J. S. (2009). Inhibition of poly (ADP-ribose) polymerase in tumors from <i>BRCA</i> mutation carriers. <i>New England Journal of Medicine, 361</i>, 123-134. doi:10.1056/NEJMoa0900212

Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., & Gourley, C. (2010). Poly (ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer cor-relating with platinum-free interval. <i>Journal of Clinical Oncology, 28</i>, 2512-2519.

Foulkes, W. D. (2006). <i>BRCA1</i> and <i>BRCA2</i>: Chemosensitivity, treatment outcomes, and prognosis. <i>Familial Cancer, 5</i>, 135-142. doi:10.1007/s10689-005-2832-5

Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., … Offit, K. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <i>New England Journal of Medicine, 346</i>, 1609-1615.

Lacour, R. A., Daniels, M. S., Westin, S. N., Meyer, L. A., Burke, C. C., Burns, K. A., … Lu, K. H. (2008). What women with ovarian cancer think and know about genetic testing. <i>Gynecologic Oncology, 111</i>, 132-136. doi:10.1016/j.ygyno.2008.06.016

Meiser, B., Gleeson, M., Kasparian, N. A., Barlow-Stewart, K., Ryan, M., & Watts, K. (2012). There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. <i>Gynecologic Oncology, 124</i>, 153-157.

Meiser, B., Mitchell, P., McGirr, H., Van Herten, M., & Schofield, P. (2005). Implications of genetic risk information in families with a high density of bipolar disorder: An exploratory study. <i>Social Science and Medicine, 60</i>, 109-118. doi:10.1016/j.socscimed.2004.04.016

Miles, M. B., & Huberman, A. M. (1994). <i>Qualitative data analysis: An expanded sourcebook</i> (2nd ed.). London, England: Sage.

Myriad Genetic Laboratories. (2012). <i>BRCA1</i> and <i>BRCA2</i> prevalence tables. Retrieved from <a target="_blank" href='http://www.myriadpro.com/bracanalysis-prevalence-tables'>http://www.myri...

Patton, M. (1980). <i>Qualitative evaluation and research methods</i> (2nd ed.). Newbury Park, CA: Sage.

Patton, M. (2002). <i>Qualitative evaluation and research methods</i> (3rd ed.). Thousand Oaks, CA: Sage.

Pitman, M. A., & Maxwell, J. A. (1992). Qualitative approaches to evaluation: Models and methods. In M. D. LeCompte, W. L. Millroy, & J. Preissle (Eds.), <i>Handbook of qualitative research in education</i> (pp. 729-770). San Diego, CA: Academic Press.

Quinn, J. E., James, C. R., Stewart, G. E., Mulligan, J. M., White, P., Chang, G. K., … Harkin, D. P. (2007). <i>BRCA1</i> mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. <i>Clinical Cancer Research, 13</i>, 7413-7420.

Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. E., … Weber, B. L. (2002). Prophylactic oophorectomy in carriers of <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>New England Journal of Medicine, 346</i>, 1616-1622.

Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Kwan, E., … Narod, S. A. (2001). Prevalence and penetrance of germline <i>BRCA1</i> and <i>BRCA2</i> mutations in a population series of 649 women with ovarian cancer. <i>American Journal of Human Genetics, 68</i>, 700-710.

Schlich-Bakker, K., Ausems, M., Schipper, M., Ten Kroode, H., Warlam-Rodenhuis, C., & van den Bout, J. (2008). <i>BRCA1/2</i> mutation testing in breast cancer patients: A prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. <i>Breast Cancer Research Treatment, 109</i>, 507-514. doi:10.1007/s10549-007-9680-y

Schwartz, M., Lerman, C., Brogan, B., Peshkin, B., Hughes Halbert, C., DeMarco, T., … Isaacs, C. (2004). Impact of <i>BRCA1/2</i> counseling and testing on newly diagnosed breast cancer patients. <i>Journal of Clinical Oncology, 22</i>, 1823-1829. doi:10.1200/JCO.2004.04.086

Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Isaacs, C., DeMarco, T., … Finch, C. (2005). Utilization of <i>BRCA1/BRCA2</i> mutation testing in newly diagnosed breast cancer patients. <i>Cancer Epidemiology, Biomarkers and Prevention, 14</i>, 1003-1007. doi:10.1158/1055-9965.EPI-03-0545

Tan, D. S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., … Gore, M. E. (2008). <i>"BRCA</i>ness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Journal of Clinical Oncology, 26</i>, 5530-5536. doi:10.1200/JCO.2008.16.1703

Trainer, A. H., Meiser, B., Watts, K., Mitchell, G., Tucker, K., & Friedlander, M. (2010). Moving toward personalized medicine: Treatment-focused genetic testing of women newly diagnosed with ovarian cancer. <i>International Journal of Gynecological Cancer, 20</i>, 704-716. doi:10.1111/IGC.0b013e3181dbd1a5

Vadaparampil, S., Quinn, G., Miree, C., Brzosowicz, J., Carter, B., & Laronga, C. (2009). Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. <i>Annals Surgical Oncology, 16</i>, 1973-1981. doi:10.1245/s10434-009-0479-4

van Roosmalen, M. S., Stalmeier, P. F., Verhoef, L. C., Hoekstra-Weebers, J. E., Oosterwijk, J. C., Hoogerbrugge, N., … van Daal, W. A. J. (2004). Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. <i>American Journal of Medical Genetics, Part A, 124</i>, 346-355. doi:10.1002/ajmg.a.20374